Haematology

The Department of Hematology of Ruijin Hospital affiliated with Shanghai Jiao Tong University School of Medicine is one of the comprehensive diagnosis and treatment centers for hematological diseases with the greatest international influence in China, leading the development of China’s diagnostic and treatment system for diseases of the hematologic system and medical care, teaching, and research in hematology. The Department of Hematology of Ruijin Hospital was established in 1952, and the Shanghai Institute of Hematology was established in 1987. The Department of Hematology of Ruijin Hospital is a national key discipline, a National Key Clinical Specialty in Hematology of the Ministry of Health, a key discipline under construction under the “211” Project, and a “985” Leukemia Translational Medicine Base. It is also a Shanghai Municipality “top-priority” key discipline, a Shanghai first-class discipline, and so on. In the Fudan version of the 2021 China Hospital Rankings, released in November 2022, it ranked third nationally among hematology specialties. It possesses comprehensive diagnostic and treatment capabilities for diseases of the hematologic system, demonstrates and promotes a high-level diagnostic and treatment system, actively undertakes hematology education and talent training, develops a tiered specialist talent pool, and trains clinical technical backbone personnel. Over the past 5 years, the hematology specialty recorded more than 461,700 outpatient visits, more than 40,000 hospital admissions and discharges, and more than 900 bone marrow transplant procedures, ranking first in Shanghai. The Department of Hematology of Ruijin Hospital successively became a key laboratory of Shanghai Municipality, the Ministry of Health, and the Ministry of Education; in 2001, it became the National Key Laboratory of Medical Genomics and was rated an excellent key laboratory four times consecutively. In 2020, the research ward of the National Major Scientific and Technological Infrastructure for Translational Medicine was officially put into operation. Relying on the advanced research platforms of the Shanghai Institute of Hematology and the National Key Laboratory of Medical Genomics, as well as the systematic, large-scale, and integrated National Major Scientific and Technological Infrastructure for Translational Medicine, it is committed to translating original achievements, developing original core technologies with international standing, realizing the international leadership of Chinese original solutions, and promoting the standardized and normalized development of the diagnosis and treatment of diseases of the hematologic system in China. Over the past 5 years, the discipline has obtained more than 80 scientific research projects, including those of the National Natural Science Foundation and others, and project funding has exceeded RMB 105.996 million.